Lilly's New Weight-Loss Drug Makes Ozempic Look Like a Warm-Up

Lilly also shared 104-week data from an extension study in patients with severe obesity (BMI of 35 or higher). Those who continued on the highest dose hit 30.3% average weight loss at two years. The weight kept coming off even after the initial 80-week mark.

It's Not Just About the Scale

Weight loss is the flashy headline, but the metabolic improvements tell a deeper story. At 80 weeks, patients on retatrutide saw triglycerides drop by up to 43%, systolic blood pressure fall by up to 12.3 mmHg, and waist circumference shrink by up to 9.5 inches.

In a separate Phase 3 trial called TRIUMPH-4, Lilly tested retatrutide in patients who had both obesity and knee osteoarthritis. The 12 mg group lost 28.7% of their body weight at 68 weeks and reported a 74% reduction in knee pain scores. Placebo patients saw a 40% pain reduction. For people whose joints have been crushed under excess weight for years, this is a potential life-changer.

There's also a diabetes angle. In the TRANSCEND-T2D-1 trial, retatrutide cut HbA1c by 2 percentage points at 40 weeks, with over 90% of patients reaching normal blood sugar targets. Weight loss in the diabetes population reached about 17% at 40 weeks, which is already better than most GLP-1 drugs achieve in non-diabetic patients over longer periods.

Even sleep apnea improved. In TRIUMPH-1 participants with moderate-to-severe obstructive sleep apnea, the number of breathing interruptions per hour dropped by 36.1 from a baseline of 58.6.

The Catch (Because There's Always a Catch)

Retatrutide's side effects follow the familiar GLP-1 playbook: nausea (42% at the top dose), diarrhea (32%), constipation (26%), and vomiting (25%). These were mostly mild to moderate.

But there's a new wrinkle. A notable percentage of patients reported dysesthesia, a tingling or burning sensation. In TRIUMPH-4, it hit 20.9% of patients on the 12 mg dose versus just 0.7% on placebo. In TRIUMPH-1, about one in ten patients at higher doses experienced it. Most cases resolved on their own, and most patients stayed on the drug. Still, it's a signal the FDA will want to examine closely.

Discontinuation rates at the 12 mg dose ran about 11% in TRIUMPH-1 and 18% in TRIUMPH-4 (the osteoarthritis trial). Those aren't alarming, but they're higher than placebo and higher than what you typically see with tirzepatide.

Why Novo Nordisk Should Be Nervous

The timing of this data is brutal for Novo Nordisk. Their big next-generation bet, CagriSema (a combo of semaglutide and an amylin analog called cagrilintide), recently went head-to-head against Lilly's Zepbound and lost. CagriSema delivered about 20% weight loss at 84 weeks; Zepbound hit roughly 24%. CagriSema failed its non-inferiority endpoint, meaning it couldn't even prove it was "close enough."

Now Lilly is showing a drug that blows past Zepbound too. Retatrutide's 28% weight loss at 80 weeks makes CagriSema's 20% look like yesterday's news.

Novo isn't standing still. They have oral semaglutide for obesity (expected to launch soon), amycretin (an oral GLP-1/amylin combo), and early-stage triple-agonist work. But in the triple-agonist race specifically, Novo's programs are years behind Lilly's. They've even licensed an external triple agonist (UBT-251) to try to close the gap.

The Bigger Picture

Retatrutide isn't approved yet. Lilly is expected to file for regulatory approval in late 2026, with a potential FDA decision in 2027. Between now and then, the company needs to nail down long-term safety data (especially that dysesthesia signal) and demonstrate that the risk-benefit profile holds up under regulatory scrutiny.

But the competitive implications are already reshaping the landscape. Roche, Boehringer Ingelheim, Amgen, Pfizer, and a swarm of biotechs (Viking Therapeutics, Structure Therapeutics, Innovent) are all chasing their own multi-agonist programs. A PatentVest analysis identified 27 triple-agonist programs globally, with a significant chunk coming out of China.

The obesity drug market is entering a new phase. Single-target GLP-1 drugs were the opening act. Dual agonists like tirzepatide raised the bar. Now triple agonists are pushing weight loss toward 30% and beyond, while simultaneously tackling diabetes, joint pain, sleep apnea, and cardiovascular risk.

Lilly just fired the starting gun on the next round of this race. Everyone else is scrambling to keep up.

Zepbound Just Got a Lot Cheaper (If You Know Where to Look)

Eli Lilly just capped every Zepbound dose at $499/month through its direct-to-patient platform, slashing the top dose by over 50%. With compounding pharmacies shut down and Novo Nordisk undercutting on price, this move is less about generosity and more about locking down the obesity drug market.